<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39444701</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of concomitant SARS-CoV-2 and influenza vaccination in UK healthcare workers: a prospective longitudinal observational study.</ArticleTitle><Pagination><StartPage>101022</StartPage><MedlinePgn>101022</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101022</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2024.101022</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Co-administration of inactivated influenza vaccine (IIV) and SARS-CoV-2 vaccine may impact SARS-CoV-2 vaccine induced humoral immune responses. We aimed to compare IIV and SARS-CoV-2 vaccine induced cellular and humoral immune responses in those receiving concomitant vaccination to those receiving these vaccines separately.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a cohort study between 29th September 2021 and 5th August 2022 in healthcare workers who worked at the local NHS trust and in the surrounding area that were vaccinated with a mRNA SARS-CoV-2 booster and cell-based IIV. We measured haemagglutination inhibition assay (HAI) titres, SARS-CoV-2 anti-spike antibody and SARS-CoV-2 ELISpot count pre-vaccination, 1-month and 6-months post-vaccination and evaluated differences by vaccine strategy.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">We recruited 420 participants, 234/420 (56%) were vaccinated concomitantly and 186/420 (44%) separately. The 1-month post-vaccination mean fold rise (MFR) in SARS-CoV-2 anti-spike antibodies was lower in those vaccinated concomitantly compared to separately (MFR [95% confidence interval (CI)] 9.7 [8.3, 11.4] vs 12.8 [10.3, 15.9], <i>p</i> = 0.04). After adjustment for age and sex, the adjusted geometric mean ratio (aGMR) remained lower for those vaccinated concomitantly compared to separately (aGMR [95% CI] 0.80 [0.70, 0.92], <i>p</i> = 0.001). At 6-months post-vaccination, we found no statistically significant difference in SARS-CoV-2 anti-spike antibody titres (aGMR [95% CI] 1.09 [0.87, 1.35], <i>p</i> = 0.45). We found no statistically significant correlation between vaccine strategy with SARS-CoV-2 ELISpot count and influenza HAI titres at 1-month and 6-months post-vaccination.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Our study found that concomitant vaccination with SARS-CoV-2 and IIV has no statistically significant impacts on long-term immunogenicity. Further research is required to understand the underlying mechanisms and assess the clinical significance of reduced anti-spike antibodies in those vaccinated concomitantly.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Research and Innovation (UKRI) through the COVID-19 National Core Studies Immunity (NCSi) programme (MC_PC_20060).</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nazareth</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development Centre for Population Health, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development Centre for Population Health, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development Centre for Population Health, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Centre for Health Information and Discovery, Oxford Big Data Institute, University of Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barr</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sheena G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peck</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veli</LastName><ForeName>Neyme</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Mrinal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development Centre for Population Health, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gohar</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development Centre for Population Health, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teece</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vail</LastName><ForeName>Denny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research Space, University Hospitals of Leicester NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renals</LastName><ForeName>Val</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Research Space, University Hospitals of Leicester NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karia</LastName><ForeName>Aleesha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Space, University Hospitals of Leicester NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renals</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Space, University Hospitals of Leicester NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tattersall</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Revvity (Certimmune), Abingdon, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otter</LastName><ForeName>Ashley D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haldar</LastName><ForeName>Pranab</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephenson</LastName><ForeName>Iain</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiselka</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Julian W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nellums</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Lifespan and Population Health Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Population Health, University of New Mexico, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pareek</LastName><ForeName>Manish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester NIHR Biomedical Research Centre, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development Centre for Population Health, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine co-administration</Keyword></KeywordList><CoiStatement>PM has received honoraria from Moderna, BioNTech, Gilead, AstraZeneca and GSK, support for attending meetings from AstraZeneca and has participated on an advisory board for AstraZeneca and Moderna. IB declares shares in an influenza vaccine manufacturing company. PH received an honorarium for hosting a COVID-19 webinar, on behalf of Oxford Immunotec (now Revvity) who are manufacturers of the ELISpot technology used in the manuscript. AT is an employee of Revvity. MP reports grants from UKRI-MRC for the current work and UKRI-MRC, NIHR, Sanofi, Gilead and Moderna outside the current work and has received consulting fees from QIAGEN. SGS reports consultancy or advisory role for CSL Seqirus, Novavax, Moderna, Sanofi and Evo Health. The WHO Collaborating Centre for Reference and Research on Influenza received funding from the International Federation of Pharmaceutical Manufacturers and Associations and from CSL Seqirus for the production of influenza vaccines. DP is supported by a NIHR Doctoral Research Fellowship. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444701</ArticleId><ArticleId IdType="pmc">PMC11496956</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2024.101022</ArticleId><ArticleId IdType="pii">S2666-7762(24)00189-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nka A.D., Ka'e A.C., Bouba Y., et al. Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: a systematic review and meta-analysis protocol. PLoS One. 2022;17(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362926</ArticleId><ArticleId IdType="pubmed">35943981</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano A.D., Roguski K.M., Chang H.H., et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935243</ArticleId><ArticleId IdType="pubmed">29248255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Self W.H., Naioti E.A., et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated Hospitalizations among adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1156–1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389395</ArticleId><ArticleId IdType="pubmed">34437524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazareth J., Barr I., Sullivan S.G., et al. Intra-season waning of immunity following the seasonal influenza vaccine in early and late vaccine recipients. J Infect. 2022;85(6):e172–e174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556766</ArticleId><ArticleId IdType="pubmed">36243199</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriyama M., Hugentobler W.J., Iwasaki A. Seasonality of respiratory viral infections. Annu Rev Virol. 2020;7(1):83–101.</Citation><ArticleIdList><ArticleId IdType="pubmed">32196426</ArticleId></ArticleIdList></Reference><Reference><Citation>Early advice on 2021 influenza vaccination. Australian Government Department of Health and Aged Care; 2021.</Citation></Reference><Reference><Citation>Lazarus R., Baos S., Cappel-Porter H., et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398(10318):2277–2287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585490</ArticleId><ArticleId IdType="pubmed">34774197</ArticleId></ArticleIdList></Reference><Reference><Citation>Toback S., Galiza E., Cosgrove C., et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(2):167–179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598212</ArticleId><ArticleId IdType="pubmed">34800364</ArticleId></ArticleIdList></Reference><Reference><Citation>Organisation WH . 2021. Coadministration of seasonal inactivated influenza and COVID-19 vaccines. (Interim guidance)</Citation></Reference><Reference><Citation>Van Buynder P.G., Newbound A., MacIntyre C.R., Kennedy A.T., Clarke C., Anderson J. Australian experience of the SH21 flu vaccination program during the COVID-19 vaccine program. Hum Vaccines Immunother. 2021;17(11):4611–4616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828056</ArticleId><ArticleId IdType="pubmed">34542384</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenyu W., Xiaoqian D., Bo C., et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: a randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China. Vaccine. 2022;40(36):5356–5365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9343811</ArticleId><ArticleId IdType="pubmed">35933275</ArticleId></ArticleIdList></Reference><Reference><Citation>Radner H., Sieghart D., Jorda A., et al. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers. Clin Microbiol Infect. 2023;29(5):635–641.</Citation><ArticleIdList><ArticleId IdType="pubmed">36509374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulfer E.A., Geckin B., Taks E.J.M., et al. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial. Lancet Reg Health Europe. 2023;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10091277</ArticleId><ArticleId IdType="pubmed">37261212</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen C., Mosnier A., Gavazzi G., et al. Coadministration of seasonal influenza and COVID-19 vaccines: a systematic review of clinical studies. Hum Vaccin Immunother. 2022;18(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9746457</ArticleId><ArticleId IdType="pubmed">36256633</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin C.A., Nazareth J., Jarkhi A., et al. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. eClinicalMedicine. 2023;58:101926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10071048</ArticleId><ArticleId IdType="pubmed">37034357</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics OfN . 2021. Ethnic group, national identity and religion.</Citation></Reference><Reference><Citation>World Health Organization = Organisation mondiale de la S Recommended composition of influenza virus vaccines for use in the 2021–2022v northern hemisphere influenza season – Composition recommandée des vaccins antigrippaux pour la saison grippale 2021-2022 dans l’hémisphère Nord. Wkly Epidemiol Rec. 2021;96(11):77–88.</Citation></Reference><Reference><Citation>Katz J.M., Hancock K., Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669–683.</Citation><ArticleIdList><ArticleId IdType="pubmed">21692672</ArticleId></ArticleIdList></Reference><Reference><Citation>StataCorp . College Station TSL. 2024. Stata statistical software: release 17.</Citation></Reference><Reference><Citation>Equality and inclusion annual report. 2019. http://www.library.leicestershospitals.nhs.uk/EandD/Shared%20Documents/Equality%20and%20Diversity/Equality%20Annual%20Report%202018-19%20-%20final.pdf Available from:</Citation></Reference><Reference><Citation>Gonen T., Barda N., Asraf K., et al. Immunogenicity and reactogenicity of coadministration of COVID-19 and influenza vaccines. JAMA Netw Open. 2023;6(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10492184</ArticleId><ArticleId IdType="pubmed">37682571</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck R.W., Jr., Gurtman A., Rubino J., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19(8):1296–1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3416075</ArticleId><ArticleId IdType="pubmed">22739693</ArticleId></ArticleIdList></Reference><Reference><Citation>Aplasca-De Los Reyes M.R., Dimaano E., Macalalad N., et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother. 2012;8(7):881–887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3495724</ArticleId><ArticleId IdType="pubmed">22485048</ArticleId></ArticleIdList></Reference><Reference><Citation>Izikson R., Brune D., Bolduc J.S., et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022;10(4):392–402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803382</ArticleId><ArticleId IdType="pubmed">35114141</ArticleId></ArticleIdList></Reference><Reference><Citation>De Beuckelaer A., Pollard C., Van Lint S., et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol Ther. 2016;24(11):2012–2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5154477</ArticleId><ArticleId IdType="pubmed">27506450</ArticleId></ArticleIdList></Reference><Reference><Citation>Didierlaurent A.M., Lambert P.-H. Co-administration of COVID-19 and influenza vaccines. Clin Microbiol Infection. 2023;29(5):558–559.</Citation><ArticleIdList><ArticleId IdType="pubmed">36773770</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyton R.J., Altmann D.M. Redirected vaccine imprinting by co-administration of COVID-19 and influenza vaccines. Lancet Reg Health Europe. 2023;29:100644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10170310</ArticleId><ArticleId IdType="pubmed">37261213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Steain M., Reynaldi A., et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52–e61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592563</ArticleId><ArticleId IdType="pubmed">34806056</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle K.A., Ambrosino D.M., Fiore-Gartland A., et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423–4428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntronwong N., Assawakosri S., Kanokudom S., et al. Strong correlations between the binding antibodies against wild-type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (Third-Dose) vaccination. Diagnostics. 2022;12(8):1781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9394243</ArticleId><ArticleId IdType="pubmed">35892491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothmann M.D., Wiens B.L., Chan I.S. CRC Press; 2011. Design and analysis of non-inferiority trials.</Citation></Reference><Reference><Citation>Chalkias S., Eder F., Essink B., et al. Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022;28(11):2388–2397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671805</ArticleId><ArticleId IdType="pubmed">36202997</ArticleId></ArticleIdList></Reference><Reference><Citation>Venuto R., Giunta I., Cortese R., et al. The importance of COVID-19/influenza vaccines co-administration: an essential public health tool. Infect Dis Rep. 2022;14(6):987–995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9778301</ArticleId><ArticleId IdType="pubmed">36547244</ArticleId></ArticleIdList></Reference><Reference><Citation>Veli N., Martin C.A., Woolf K., et al. Hesitancy for receiving regular SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis from the UK-REACH study. BMC Med. 2022;20(1):386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9548389</ArticleId><ArticleId IdType="pubmed">36210437</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193.</Citation><ArticleIdList><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–168.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott P., Bodinier B., Eales O., et al. Rapid increase in omicron infections in England during December 2021: REACT-1 study. Science. 2022;375(6587):1406–1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939772</ArticleId><ArticleId IdType="pubmed">35133177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>